Skip to Content

MILRINONE 1MG/ML SOLUTION FOR INJECTION/INFUSION

Active substance(s): MILRINONE

View full screen / Print PDF » Download PDF ⇩
Transcript
PACKAGE LEAFLET: INFORMATION FOR THE USER
Milrinone 1mg/ml Solution for injection/infusion
Milrinone
Read all of this leaflet carefully
before you start taking this
medicine because it contains
important information for you.
• Keep this leaflet. You may need to
read it again.
• If you have any further questions,
ask your doctor, nurse or pharmacist.
• This medicine has been
prescribed for you only. Do not
pass it on to others. It may harm
them, even if their signs of illness
are the same as yours.
• If you get any side effects, talk to your doctor, nurse or
pharmacist. This includes any possible side effects not listed in
this leaflet. See section 4.
What is in this leaflet:
1. What Milrinone is and what it is used for
2. What you need to know before you are given Milrinone
3. How you will be given Milrinone
4. Possible side effects
5. How to store Milrinone
6. Contents of the pack and other information
1. WHAT MILRINONE IS AND WHAT IT IS USED FOR
The name of your medicine is Milrinone 1mg/ml Solution for
injection/infusion (referred to as Milrinone throughout this
leaflet). It contains a medicine called milrinone. This belongs to
a group of medicines called phosphodiesterase inhibitors. It
works by making your heart muscle contract more strongly and
your blood vessels become wider. This means blood can flow
more easily making your heart pump blood more successfully.
Milrinone can be used in adults for:
• Short-term treatment of severe congestive heart failure
(where the heart cannot pump enough blood to the rest of
the body) when other medicines have not worked
• Treatment after a heart operation for when your heart is
having difficulty pumping blood around your body
Milrinone can be used in children for
• short term treatment (up to 35 hours) of severe congestive
heart failure (where the heart cannot pump enough blood to
the rest of the body) when other medicines have not worked
• short term treatment (up to 35 hours) of acute heart failure
after a heart operation i.e. when your heart is having
difficulty pumping blood around your body.
2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN
MILRINONE
You should not be given Milrinone if:
• you are allergic (hypersensitive) to milrinone or any of the
other ingredients of this medicine (listed in Section 6). Signs
of an allergic reaction include: a rash, swallowing or breathing
problems, swelling of your lips, face, throat or tongue
• you have lost body fluids and are severely dehydrated.
Do not have this medicine if any of the above apply to you. If
you are not sure, talk to your doctor, nurse or pharmacist before
having Milrinone.
Warnings and precautions
Talk to your doctor, nurse or pharmacist before you are given
milrinone if you:
• are having or have just had a heart attack
• have severe heart valve problems such as narrowing,
thickening or blockage of your heart valves
• have uneven or uncontrolled fast heartbeats. You may also be
experiencing pounding in your chest, light-headedness,
fainting and shortness in breath
• have low blood pressure which may make you feel dizzy,
light-headed or faint
• have previously taken water tablets (diuretics) which caused
you to have heart problems
• have low levels of potassium in your blood. Your doctor may
do blood tests to check this
• have kidney problems
If you are not sure if any of the above apply to you, talk to your
doctor, nurse or pharmacist before having Milrinone.
The following should be considered in addition to warnings and
precautions described for adults.
Children and adolescents
Before giving Milrinone, your doctor will check a lot of
parameters such as heart rhythm and blood pressure. He/she
INFORMATION FOR THE HEALTHCARE PROFESSIONAL
Milrinone 1mg/ml Solution for injection/infusion
Please refer to the Summary of Product Characteristics (SmPC)
for further details on this product.
Qualitative and Quantitative Composition
Each 10 ml ampoule contains 10 mg milrinone. Each ml of
solution contains 1 mg milrinone.
Excipient with known effect:
Sodium (this medicinal product contains less than 1 mmol
sodium (23 mg) per dose)
Pharmaceutical Form
Solution for injection/infusion.
Clear, colourless to pale yellow solution, practically free from
particles.
The pH of the solution is 3.2 - 4.0 and the osmolality is
261 – 319mOsm/Kg.
Therapeutic Indications
Milrinone Injection is indicated for the short-term treatment of
severe congestive heart failure unresponsive to conventional
maintenance therapy, and for the treatment of patients with
acute heart failure, including low output states following
cardiac surgery.
In paediatric population milrinone is indicated for the short-term
treatment (up to 35 hours) of severe congestive heart failure
unresponsive to conventional maintenance therapy (glycosides,
diuretics, vasodilators and/or angiotensin converting enzyme
(ACE) inhibitors), and for the short-term treatment (up to 35
hours) of paediatric patients with acute heart failure, including
low output states following cardiac surgery.
Posology and method of administration
For intravenous administration.
Adults: Milrinone Injection should be given as a loading dose of
50μg/kg administered over a period of 10 minutes usually
followed by a continuous infusion at a dosage titrated between
0.375μg/kg/min and 0.75μg/kg/min according to
haemodynamic and clinical response, but should not exceed
1.13mg/kg/day total dose. For instructions on dilution of the
product before administration and a guide to maintenance
infusion delivery rates, see the information under “Special
precautions for disposal and other handling”.
Solutions of different concentrations may be used according to
patient fluid requirements. The duration of therapy should
depend upon the patient's response. In congestive cardiac
failure, patients have been maintained on the infusion for up to

will order blood tests as well.
The infusion will not start if your child’s heart rhythm and blood
pressure is not stable.
Please tell your doctor if your child:
• has kidney problems
• is a preterm infant or has a low birth weight
• has a certain heart problem named Patent Ductus Arteriosus:
a connection between two major blood vessels (aorta and
pulmonary artery) which persists though it should be closed.
In these cases, your doctor will decide if your child will be
treated with Milrinone.
Other medicines and Milrinone
Please tell your doctor, nurse or pharmacist if you are taking or
have recently taken any other medicines. This includes
medicines you buy without a prescription, including herbal
medicines. This is because Milrinone can affect the way some
other medicines work. Also some medicines can affect the way
Milrinone works.
In particular, tell your doctor, nurse or pharmacist if you are taking:
• digoxin (used for heart problems)
• water tablets (diuretics)
• medicines used to treat high blood pressure or angina (chest
pain) such as amlodipine, nifedipine or felodipine.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be
pregnant or are planning to have a baby, ask your doctor, nurse
or pharmacist for advice before taking this medicine.
Milrinone contains sodium
This medicinal product contains less than 1mmol sodium
(23mg) per dose.
3. HOW YOU WILL BE GIVEN MILRINONE
Milrinone will always be given by your doctor or nurse. This is
because it needs to be given as an injection. It is administered
into a vein.
Having this medicine
• This medicine is usually given in a ‘drip’ after being diluted
using either 0.45% sodium chloride infusion, 0.9% sodium
chloride infusion or 5% glucose infusion
• If you feel the effect of your medicine is too weak or too
strong, tell your doctor or nurse
How much will be given to you
• Your doctor will decide how much medicine you should have
based on your body weight
• If you have problems with your kidneys, you may be given a
lower dose
Adults and the elderly
• Your doctor should give you a first dose of 50 micrograms for
every kilogram of your weight over a period of 10 minutes
• This is then followed by a smaller dose between 0.375 and
0.75 micrograms for every kilogram of body weight per
minute, as needed
• The medicine is usually given for 2 to 3 days, but it may be
given for up to 5 days
• If you are having this medicine after a heart operation, it will
usually only be given for up to 12 hours
Use in children and adolescents
• Your doctor should give your child a first dose ranging
between 50 and 75 micrograms for every kilogram of his
weight, over a period of 30 to 60 minutes.
• This is then followed by a dose ranging from 0.25 to 0.75
micrograms for every kilogram of his/her weight per minute
according to your child’s response to the treatment and
occurrence of side effects. Milrinone can be given for up to
35 hours.
During infusion, your child will be closely monitored: your
doctor will check a lot of parameters such as heart rhythm and
blood pressure and blood will be taken to evaluate the response
to therapy and occurrence of side effects.
If you receive more Milrinone than you should
It is unlikely that your doctor or nurse will give you too much of
this medicine. Your doctor and nurse will check your progress
and the medicine that you are given. Always ask if you are not
sure why you are getting a dose of medicine. The following
effects may happen if you have too much Milrinone: feeling
dizzy, light-headedness and fainting (due to low blood
pressure) and an uneven heartbeat.
If you miss a dose of Milrinone
Your doctor or nurse will have instructions on when to give you
this medicine. It is unlikely that you will not be given the
medicine as it has been prescribed. However, if you do think you
have missed a dose, tell your doctor or nurse.
5 days, although the usual period is 48 to 72 hours. In acute
states following cardiac surgery, it is unlikely that treatment
need be maintained for more than 12 hours.
Renal Impairment: Dosage adjustment required. Data obtained
from patients with severe renal impairment but without heart
failure have demonstrated that the presence of renal
impairment significantly increases the terminal elimination
half-life of milrinone. For patients with clinical evidence of renal
impairment, the loading dose is not affected, but the infusion
rate should be adjusted according to haemodynamic response.
Recommended maintenance infusion rates are provided under
“Special precautions for disposal and other handling”.
Elderly: Experience so far suggests that no special dosage
recommendations are necessary.
Paediatric population:
In published studies selected doses for infants and children were:
• Intravenous loading dose: 50 to 75 μg/kg administered over
30 to 60 minutes.
• Intravenous continuous infusion: To be initiated on the basis
of hemodynamic response and the possible onset of
undesirable effects between 0.25 to 0.75 μg/kg/min for a
period up to 35 hours.
In clinical studies on low cardiac output syndrome in infants and
children under 6 years of age after corrective surgery for
congenital heart disease 75 μg/kg loading dose over 60 minutes
followed by a 0.75 μg/kg/min infusion for 35 hours significantly
reduced the risk of development of low cardiac output syndrome.
Results of pharmacokinetic studies (see section 5.2 of the SmPC)
have to be taken into consideration.
Renal impairment:
Due to lack of data the use of milrinone is not recommended in
paediatric population with renal impairment (for further
information please see section 4.4 of the SmPC).
Patent ductus arteriosus:
If the use of milrinone is desirable in preterm or term infants at
risk of/with patent ductus arteriosus, the therapeutic need must
be weighed against potential risks (see sections 4.4, 4.8, 5.2,
and 5.3 of the SmPC).
Pharmaceutical Particulars
List of excipients
(S)-Lactic Acid
Anhydrous Glucose
Water for Injections
Sodium Hydroxide (for pH adjustment)
Lactic Acid (for pH adjustment)

If you stop having Milrinone
Keep having Milrinone until your doctor tells you to stop. Do not
stop having Milrinone just because you feel better. If you stop,
your illness may get worse.
Tests
Your doctor or nurse will use an electrocardiogram (ECG) to
check how well your heart works. They will also carry out blood
tests and check your blood pressure and pulse rate.
If you have any further questions on the use of this medicine,
ask your doctor or nurse.
4. POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects,
although not everybody gets them.
Stop having Milrinone and tell your doctor straight away
if:
• You have an allergic reaction. The signs may include: a rash,
swallowing or breathing problems, swelling of your lips, face,
throat or tongue, fainting or losing consciousness. The
chances of this happening are very rare
Tell a doctor or nurse straight away if you notice any of
the following side effects:
Common (affects less than 1 in 10 people)
• Uneven, increased or fast heartbeats. You may also experience
pounding in your chest, feel light-headed, faint or short of
breath
Uncommon (affects less than 1 in 100 people)
• Ventricular fibrillation – a serious heart rhythm problem.
Signs of this include very fast, uneven or forceful heartbeat
(palpitations), dizziness and loss of consciousness. You may
also feel sick, have cold sweats, shortness of breath and chest
pain
• Thrombocytopenia – a blood problem. Signs of this are that
you may bruise more easily than usual
• Chest pain
Very rare (affects less than 1 in 10,000 people)
• Torsades de Pointes – a serious heart rhythm problem. Signs
of this include very fast, uneven or forceful heartbeat
(palpitations), dizziness and loss of consciousness. You may
also feel sick, have cold sweats, shortness of breath, unusual
pale complexion and chest pain
• Difficulty breathing, wheezing or tightness in the chest
Tell a doctor or nurse as soon as possible if you notice
any of the following side effects:
Common (affects less than 1 in 10 people)
• Low blood pressure. Signs of this include feeling dizzy,
lightheaded or fainting. If you also notice signs like a fast or
uneven heartbeat or chest pain this could be a more serious
side effect (see above)
• Headache
Uncommon (affects less than 1 in 100 people)
• Feeling shaky
• Low levels of potassium in your blood. Signs of this are
tiredness, confusion, muscle weakness and muscle cramps.
This may be due to low levels of potassium in your body.
Tell a doctor or nurse if any of the following side effects
gets serious or lasts longer than a few days
Very Rare (affects less than 1 in 10,000 people)
• Skin rashes including at the site of the injection
Uncommon (affects less than 1 in 100 people)
• A blood test may show changes in the way the liver is working
Talk to your doctor, nurse or pharmacist if any of the side effects
gets serious or lasts longer than a few days, or if you notice any
side effects not listed in this leaflet.
In addition to side effects observed in adults, the following were
reported in children and adolescents:
Additional side effects in children and adolescents
Frequency not known:
• Bleeding into the fluid-filled areas (ventricles) surrounded by
the brain (intraventricular haemorrhage)
• A heart problem known as Patent Ductus Arteriosus: a
connection between two major blood vessels (aorta and
pulmonary artery) which persists though it should be closed.
This can cause excess fluid in the lungs, bleedings, destruction
of the bowel or part of the bowel and possibly be fatal
• Changes in the way the kidneys are working if you already
have low blood pressure.
Moreover, compared to adults, decrease in the number of
platelets in the blood seems to occur more often in children and
the risk of this side effect is increased with the duration of the
Milrinone infusion. Heart rhythm troubles seem to occur less
often in children than in adults.

Incompatibilities
Furosemide or bumetanide should not be administered in
intravenous lines containing Milrinone Injection since
precipitation occurs on admixture. Sodium Bicarbonate
Intravenous infusion should not be used for dilution.
Other drugs should not be mixed with Milrinone Injection until
further compatibility data are available.
Shelf life
18 months for the unopened product
Chemical and physical in-use stability has been demonstrated
for 48 hours at 5°C when diluted with 0.45% sodium chloride
infusion, 0.9% sodium chloride infusion or 5% glucose infusion.
From a microbiological point of view, the product should be
used immediately. If not used immediately, in-use storage times
and conditions prior to use are the responsibility of the user and
would normally not be longer than 24 hours at 2 to 8°C, unless
dilution has taken place in controlled and validated aseptic
conditions.
Special precautions for storage
Store below 25°C. Do not freeze. Store in the original package.
For storage conditions of the medical product after dilution,
please refer to the information above, under “Shelf life”.
Nature and contents of container
Milrinone 1mg/ml Solution for Injection is presented in 10ml
clear, neutral glass (PhEur, Type I) ampoules. The ampoules are
packed in a PVC tray and cardboard box in packs of 10.
Special precautions for disposal and other handling
Instructions for dilution:
Infusion solutions should be freshly prepared before use.
Parenteral drug products should be examined visually and
should not be used if particulate matter or discolouration are
present.
The following diluents may be used to prepare solutions for
infusion:
0.45% sodium chloride infusion
0.9% sodium chloride infusion
5% glucose infusion
A solution containing 200 μg/ml milrinone should be prepared
by taking the contents of a 10 ml ampoule and adding 40 ml of
one of the above diluents (400 ml diluent per 100 ml Milrinone
Injection).
For single use. Discard any unused solution.

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or
nurse. This includes any possible side effects not listed in this
leaflet. You can also report side
effects directly via the national
reporting systems listed below:
United Kingdom:
Yellow Card Scheme
Website:
www.mhra.gov.uk/yellowcard
Ireland:
HPRA Pharmacovigilance,
Earlsfort Terrace, IRL - Dublin 2;
Tel: +353 1 6764971;
Fax: +353 1 6762517; Website: www.hpra.ie;
e-mail: medsafety@hpra.ie
Malta:
ADR Reporting, Website:
www.medicinesauthority.gov.mt/adrportal
By reporting side effects you can help provide more information
on the safety of this medicine.
5. HOW TO STORE MILRINONE
• Keep out of the sight and reach of children
• This medicine is for single use; any unused contents should
be discarded
• This medicine should not be used after the expiry date which
is stated on the carton and ampoule label after ‘EXP’. The
expiry date refers to the last day of that month
• Store below 25°C. Do not freeze. Store in the original
package.
• After dilution: Diluted solutions of Milrinone have been
shown to be chemically and physically stable when stored for
48 hours at 5°C. From a microbiological point of view, the
product should be used immediately. If not used
immediately, in-use storage times and conditions prior to use
are the responsibility of the user
• Medicines should not be thrown away via wastewater or
household waste. Your doctor, nurse or pharmacist will
dispose of medicines no longer required. These measures will
help protect the environment.
6. CONTENTS OF THE PACK AND OTHER INFORMATION
What Milrinone contains
The active substance is: milrinone. Each 10 ml ampoule
contains 10 mg milrinone. Each ml of solution contains 1 mg
milrinone.
The other ingredients are: (S)-lactic acid, anhydrous glucose,
water for injections and the pH adjusters sodium hydroxide and
lactic acid (see end of section 2).
What Milrinone looks like and contents of the pack
Milrinone is a clear, colourless to pale yellow, sterile solution,
practically free from particles. It is supplied in 10ml clear,
neutral glass (Type I, PhEur) ampoules. It is available in packs of
ten ampoules.
Marketing Authorisation Holder
Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF,
United Kingdom
Manufacturer
CP Pharmaceuticals Ltd, Ash Road North, Wrexham, LL13 9UF,
United Kingdom
Other sources of information
To listen to or request a copy of this leaflet in Braille, large print
or audio please call, free of charge: 0800 198 5000 (UK only).
Please be ready to give the following information:
Product name
Reference number
Milrinone 1mg/ml
Solution for injection/infusion
29831/0619
This is a service provided by the Royal National Institute of Blind
People.
For the Republic of Ireland and Malta please call
+44 1978 661261.
This medicinal product is authorised in the Member
States of the EEA under the following names:
United Kingdom, Ireland and Malta: Milrinone 1mg/ml Solution
for injection/infusion
This leaflet was last revised in 07/2016
107658/1

Delivery rates:
Adults:
The following provides a guide to maintenance infusion delivery
rate based upon a solution containing milrinone 200μg/ml,
prepared as described above.
Milrinone Injection Dose Infusion Delivery Rate
(µg /kg/min)
(ml/kg/hr)
0.375
0.11
0.400
0.12
0.500
0.15
0.600
0.18
0.700
0.21
Renal impairment:
The following maintenance infusion rates are recommended
using the infusion solution described above.
Creatinine
Milrinone
Maintenance
Clearance
Injection Dose
Infusion
(ml/min/1.73m2) (µg/kg/min)
Delivery Rate
(ml/kg/hr)
5
0.20
0.06
10
0.23
0.07
20
0.28
0.08
30
0.33
0.10
40
0.38
0.11
50
0.43
0.13
The infusion rate should be adjusted according to
haemodynamic response. See the information under “Posology
and method of administration.”
Marketing Authorisation Holder
Wockhardt UK Ltd
Ash Road North
Wrexham
LL13 9UF
United Kingdom
Marketing Authorisation Number(s)
PL 29831/0619
PA 1339/68/1
MA 154/10101
Date of Revision of the Text
07/2016
107658/1

pg2/2

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide